MNKD (MannKind) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNKD MannKind Corp MNKD
66 GF Score
Price $4.22
GF Value $7.40
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MannKind Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

MNKD
66GF Score
MannKind Corp MNKD
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MannKind (MNKD) Overvalued in 2026?

Based on GuruFocus' analysis, MannKind stock appears to be undervalued. The current stock price of $4.22 is trading 43% below its estimated GF Value™ of $7.40. GuruFocus considers MannKind to be Possible Value Trap.

Key valuation signals for MNKD:

  • Dividend-Payout-to-FFO:
  • GF Value™: $7.40 vs. price of $4.22 (43% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the MNKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MannKind Business Description

Other Exchanges NNFN:Germany
Address 1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
66GF Score

Get the complete analysis for MNKD

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.22
Price
$7.40
GF Value